Compare LNSR & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LNSR | IXHL |
|---|---|---|
| Founded | 2004 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical Electronics | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.8M | 134.7M |
| IPO Year | N/A | N/A |
| Metric | LNSR | IXHL |
|---|---|---|
| Price | $12.56 | $0.34 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 30.5K | ★ 6.9M |
| Earning Date | 02-26-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,141,000.00 | $12,000.00 |
| Revenue This Year | $19.55 | N/A |
| Revenue Next Year | $35.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.02 | N/A |
| 52 Week Low | $8.25 | $0.08 |
| 52 Week High | $17.31 | $2.25 |
| Indicator | LNSR | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 68.69 | 38.59 |
| Support Level | $11.86 | $0.34 |
| Resistance Level | $12.09 | $0.37 |
| Average True Range (ATR) | 0.31 | 0.02 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 99.61 | 8.24 |
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.